Research
Hormonal
Newer GLP-1RAs achieve average weight loss of 15% or greater, but a substantial number of patients fail to achieve even 5% weight loss, and weight loss is lower in older adults, males, and those with type 2 diabetes.
If you are on a GLP-1RA and not losing weight, you are not alone. Older adults, men, and those with type 2 diabetes often lose less weight on average. Discuss this with your doctor to see if lifestyle adjustments or other strategies can help improve your response.
GoodQualifiesHIGH confidence
Newer GLP-1RAs can achieve average weight loss of 15% or greater and improve cardiometabolic health. There is heterogeneity in the weight loss response to GLP-1RAs, with a substantial number of patients unable to achieve 5% or greater weight. Weight loss, on average, is lower in older adults, male patients and people with type 2 diabetes.
Why this rating
The paper cites real-world data and clinical trial results regarding response heterogeneity.
Source
Opportunities to optimize lifestyle interventions in combination with <scp>glucagon‐like peptide</scp> ‐1‐based therapy
Satya Dash · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15829
narrative_reviewCited 16×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle interventions (diet and exercise) combined with GLP-1 receptor agonists (GLP-1RAs) may mitigate gastrointestinal side effects and enhance weight loss, though their efficacy requires confirmation via randomized controlled trials.Moderate
- Weight loss of 20% or higher with newer GLP-1RAs raises concerns for nutritional deficiency and sarcopenia, necessitating monitoring similar to post-bariatric surgery care.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →